<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013102</url>
  </required_header>
  <id_info>
    <org_study_id>DREAM-201</org_study_id>
    <nct_id>NCT02013102</nct_id>
  </id_info>
  <brief_title>A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome</brief_title>
  <acronym>DREAM</acronym>
  <official_title>A Randomized, Controlled, Multi-center Collaborative Phase Ⅳ Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment
      of Myelodysplastic Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total subjects: 240, doseⅠgroup of 120 patients, doseⅡgroup of 120 patients. Subjects are
      stratified randomize. If necessary, participants accepted best supportive therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.</measure>
    <time_frame>2-4 months</time_frame>
    <description>The primary efficacy evaluation: ORR The secondary efficacy evaluation: CR，mCR，PR，HI, PFS in one year, Cytogenetic response, transfusion requirements, et al.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm Ⅰ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine Injection 20mg/m2/d*5d, IV&gt; 1h, one cycles per 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Ⅱ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine Injection 12mg/m2/d*8d, IV&gt; 1h, one cycles per 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine Injection</intervention_name>
    <description>Decitabine Injection 20mg/m2/d*5d, IV&gt; 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV&gt; 1h, one cycles per 4 weeks.</description>
    <arm_group_label>Arm Ⅰ</arm_group_label>
    <arm_group_label>Arm Ⅱ</arm_group_label>
    <other_name>qingweike</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18;

          -  The diagnosis of MDS patients comply WHO2008 standards;

          -  IPSS score≥0.5;

          -  WHO classification for patients RCUD, RARS and transfusion-dependent RCMD;

          -  ECOG PS score: 0-2;

          -  Expected survival≥3 months;

          -  Serum bilirubin≤1.5*ULN, serum ALT and AST≤2.5*ULN, serum Cr≤1.5*ULN;

          -  Subjects signed informed consent form in line with GCP requirements.

        Exclusion Criteria:

          -  Can not marrow biopsy;

          -  Previously diagnosed AML;

          -  Received azacitidine or decitabine treatment any time before;

          -  Being diagnosed with other malignancies in the prior 12 months;

          -  Pregnant or lactating women;

          -  Failure to control systemic fungal, bacterial or viral infection;

          -  Known or suspected allergy to decitabine;

          -  Known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral
             infection;

          -  Have a history of neurological or psychiatric disorders, including epilepsy or
             dementia;

          -  CTCAE 3 or 4 degree peripheral neuropathy;

          -  According to the investigator's judgment, there are concomitant diseases with a
             serious safety hazard or affect the patients completed the study in patients;

          -  Using other experimental drugs or participating in other clinical trials in the prior
             one months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao Zonghong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Hui, MD</last_name>
    <phone>0086-022-60362636</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIU HUI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shao Zonghong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

